Healthcare Shareholders Await Recovery Amid Dividend Payouts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: NASDAQ.COM
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 82.920
Low
102.00
Averages
111.76
High
120.00
Current: 82.920
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MEDTRONIC PLC ANTICIPATES NO SIGNIFICANT EFFECT ON BUSINESS OR FINANCIAL PERFORMANCE, ACCORDING TO SEC FILING
Material Impact on Business: Medtronic PLC does not anticipate any material impact on its business due to recent developments.
Financial Results Context: The statement was made in the context of the company's financial results and SEC filing.
See More
Three Healthcare Giants Maintain Dividends Amid Slow Growth
- Bristol Myers' Challenges: Despite facing stiff competition from biosimilars and slow revenue growth, Bristol Myers has increased its dividend by 28.6% over the past five years, currently offering a 4.3% yield, indicating the company's ability to maintain stable shareholder returns even in adversity.
- Medtronic's Transformation: By spinning off its diabetes care unit, Medtronic aims to enhance profitability and has launched new products like Pulse Field Ablation devices, achieving its fastest revenue growth in years, with a 3.3% dividend yield and 48 consecutive years of payout increases, reflecting its strong financial foundation and commitment to shareholder returns.
- Gilead Sciences' Diversification: Gilead's revenue has been impacted by its COVID-19 treatment Veklury, but its leadership in the HIV drug market and a robust oncology pipeline will help reduce reliance on single products, with a 2.5% dividend yield and a 42.3% cash payout ratio, providing room for future dividend increases.
- Investor Confidence: Despite growth challenges faced by these three companies, their ongoing dividend policies attract many investors, demonstrating that stable dividend payments remain a crucial factor in drawing investor interest in uncertain market conditions.
See More
Three Dividend Stocks Worth Considering
- Bristol Myers Squibb's Dividend Stability: Despite facing fierce competition from biosimilars, Bristol Myers Squibb has maintained its dividend program, with a 28.6% increase over the past five years and a current yield of 4.3%, demonstrating the company's commitment to shareholders even in adversity.
- Medtronic's Growth Strategy: Medtronic has achieved its fastest revenue growth in years by spinning off its diabetes care unit and launching new products, particularly its Pulse Field Ablation devices, with a dividend yield of 3.3% and a track record of increasing dividends for 48 consecutive years.
- Gilead Sciences' Diversification Progress: Although Gilead Sciences' revenue has been impacted by its COVID-19 treatment Veklury, it remains a leader in the HIV drug market, with a current dividend yield of 2.5% and a low cash payout ratio of 42.3%, allowing room for future dividend increases.
- Investor Preference for Dividends: In the context of economic slowdowns, investors prefer companies that can maintain dividends during tough times, and these three stocks exemplify strong financial resilience and ongoing shareholder return capabilities.
See More
Medtronic Cyberattack Does Not Affect Products or Operations
- Cyberattack Overview: Medtronic experienced a cyberattack last week, but the company confirmed that the incident did not impact its products, patient safety, or manufacturing and distribution operations, demonstrating effective isolation of its IT network from product support systems.
- Business Impact Assessment: While the cyberattack raises concerns about the growing cyber risks for medical device manufacturers, Medtronic expects that the incident will not materially impact its business or financial results, indicating operational resilience.
- Industry Context: In contrast, competitor Stryker reported a destructive cyberattack last month that delayed surgeries and caused widespread business disruption, highlighting the cybersecurity challenges faced by the healthcare industry.
- Response Measures: Medtronic has activated its emergency response plans and engaged cybersecurity experts to help contain the attack, reflecting the company's proactive approach to addressing cyber threats.
See More
Medtronic Launches New Technologies to Enhance Arrhythmia Treatment
- Clinical Trial Progress: Medtronic presented early feasibility study results for the Affera mapping and ablation system at the Heart Rhythm Society Annual Meeting, showing that 65.5% of patients remained free from ventricular tachycardia (VT) recurrence six months post-myocardial infarction, indicating the technology's potential to improve patient outcomes.
- FDA Certification Acceleration: The Sphere-9 catheter received Breakthrough Device Designation from the FDA for VT treatment, providing an expedited regulatory pathway that reflects the urgent market need for safer and more effective treatment tools, potentially driving market acceptance and sales growth.
- New Study Launch: Medtronic announced the initiation of the Conquer-AF study to evaluate the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent atrial fibrillation, which is expected to provide crucial data support for the company's market expansion in cardiac electrophysiology.
- Technological Innovation Results: The Sphere-360 catheter demonstrated 100% lesion durability in a European study, further proving the technology's consistency across varied patient anatomies, which may enhance physician workflow efficiency and improve patient treatment experiences.
See More
Medtronic's Sphere-9 Catheter Shows Promising Clinical Outcomes
- Clinical Trial Results: In an early feasibility study conducted in the U.S., 65.5% of patients treated with the Sphere-9 catheter for ventricular tachycardia (VT) remained free from recurrence at six months, indicating the potential of this technology to improve patient outcomes.
- Breakthrough Device Designation: The FDA has granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway that underscores its significance and innovation in cardiac care.
- New Trial Initiation: Medtronic announced the enrollment of the first patients in the Conquer-AF trial, which aims to evaluate the safety and effectiveness of the Sphere-9 catheter in patients with recurrent atrial fibrillation, further expanding its application scope.
- Technology Expansion: The Sphere-360 catheter demonstrated 100% lesion durability in a European study, highlighting consistency across varied patient anatomies and enhancing Medtronic's competitive position in the cardiac electrophysiology market.
See More
MEDTRONIC PLC ANTICIPATES NO SIGNIFICANT EFFECT ON BUSINESS OR FINANCIAL PERFORMANCE, ACCORDING TO SEC FILING
Material Impact on Business: Medtronic PLC does not anticipate any material impact on its business due to recent developments.
Financial Results Context: The statement was made in the context of the company's financial results and SEC filing.
See More
Three Healthcare Giants Maintain Dividends Amid Slow Growth
- Bristol Myers' Challenges: Despite facing stiff competition from biosimilars and slow revenue growth, Bristol Myers has increased its dividend by 28.6% over the past five years, currently offering a 4.3% yield, indicating the company's ability to maintain stable shareholder returns even in adversity.
- Medtronic's Transformation: By spinning off its diabetes care unit, Medtronic aims to enhance profitability and has launched new products like Pulse Field Ablation devices, achieving its fastest revenue growth in years, with a 3.3% dividend yield and 48 consecutive years of payout increases, reflecting its strong financial foundation and commitment to shareholder returns.
- Gilead Sciences' Diversification: Gilead's revenue has been impacted by its COVID-19 treatment Veklury, but its leadership in the HIV drug market and a robust oncology pipeline will help reduce reliance on single products, with a 2.5% dividend yield and a 42.3% cash payout ratio, providing room for future dividend increases.
- Investor Confidence: Despite growth challenges faced by these three companies, their ongoing dividend policies attract many investors, demonstrating that stable dividend payments remain a crucial factor in drawing investor interest in uncertain market conditions.
See More
Three Dividend Stocks Worth Considering
- Bristol Myers Squibb's Dividend Stability: Despite facing fierce competition from biosimilars, Bristol Myers Squibb has maintained its dividend program, with a 28.6% increase over the past five years and a current yield of 4.3%, demonstrating the company's commitment to shareholders even in adversity.
- Medtronic's Growth Strategy: Medtronic has achieved its fastest revenue growth in years by spinning off its diabetes care unit and launching new products, particularly its Pulse Field Ablation devices, with a dividend yield of 3.3% and a track record of increasing dividends for 48 consecutive years.
- Gilead Sciences' Diversification Progress: Although Gilead Sciences' revenue has been impacted by its COVID-19 treatment Veklury, it remains a leader in the HIV drug market, with a current dividend yield of 2.5% and a low cash payout ratio of 42.3%, allowing room for future dividend increases.
- Investor Preference for Dividends: In the context of economic slowdowns, investors prefer companies that can maintain dividends during tough times, and these three stocks exemplify strong financial resilience and ongoing shareholder return capabilities.
See More
Medtronic Cyberattack Does Not Affect Products or Operations
- Cyberattack Overview: Medtronic experienced a cyberattack last week, but the company confirmed that the incident did not impact its products, patient safety, or manufacturing and distribution operations, demonstrating effective isolation of its IT network from product support systems.
- Business Impact Assessment: While the cyberattack raises concerns about the growing cyber risks for medical device manufacturers, Medtronic expects that the incident will not materially impact its business or financial results, indicating operational resilience.
- Industry Context: In contrast, competitor Stryker reported a destructive cyberattack last month that delayed surgeries and caused widespread business disruption, highlighting the cybersecurity challenges faced by the healthcare industry.
- Response Measures: Medtronic has activated its emergency response plans and engaged cybersecurity experts to help contain the attack, reflecting the company's proactive approach to addressing cyber threats.
See More
Medtronic Launches New Technologies to Enhance Arrhythmia Treatment
- Clinical Trial Progress: Medtronic presented early feasibility study results for the Affera mapping and ablation system at the Heart Rhythm Society Annual Meeting, showing that 65.5% of patients remained free from ventricular tachycardia (VT) recurrence six months post-myocardial infarction, indicating the technology's potential to improve patient outcomes.
- FDA Certification Acceleration: The Sphere-9 catheter received Breakthrough Device Designation from the FDA for VT treatment, providing an expedited regulatory pathway that reflects the urgent market need for safer and more effective treatment tools, potentially driving market acceptance and sales growth.
- New Study Launch: Medtronic announced the initiation of the Conquer-AF study to evaluate the safety and effectiveness of the Sphere-9 catheter in patients with recurrent paroxysmal or persistent atrial fibrillation, which is expected to provide crucial data support for the company's market expansion in cardiac electrophysiology.
- Technological Innovation Results: The Sphere-360 catheter demonstrated 100% lesion durability in a European study, further proving the technology's consistency across varied patient anatomies, which may enhance physician workflow efficiency and improve patient treatment experiences.
See More
Medtronic's Sphere-9 Catheter Shows Promising Clinical Outcomes
- Clinical Trial Results: In an early feasibility study conducted in the U.S., 65.5% of patients treated with the Sphere-9 catheter for ventricular tachycardia (VT) remained free from recurrence at six months, indicating the potential of this technology to improve patient outcomes.
- Breakthrough Device Designation: The FDA has granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway that underscores its significance and innovation in cardiac care.
- New Trial Initiation: Medtronic announced the enrollment of the first patients in the Conquer-AF trial, which aims to evaluate the safety and effectiveness of the Sphere-9 catheter in patients with recurrent atrial fibrillation, further expanding its application scope.
- Technology Expansion: The Sphere-360 catheter demonstrated 100% lesion durability in a European study, highlighting consistency across varied patient anatomies and enhancing Medtronic's competitive position in the cardiac electrophysiology market.
See More
